ATERONON™

ATERONON™ is based on good and mounting evidence and could potentially offer a whole new approach to the prevention of heart disease and stroke. I shall certainly look seriously at taking it myself once it becomes available.

Dr Andy Carson (Associate Dean, School of Postgraduate GP Education, Birmingham and Solihull)

For many years now, we have been trying to identify agents that may protect us from the devastating effects of a stroke. ATERONON™ is an exciting safe agent that may prove to have a major impact on this disease.

Peter Kirkpatrick (Consultant Neurovascular Surgeon at Addenbrooke's Hospital, Cambridge)

If you think that it can reduce the damage to the arteries, which is the damage that ends up causing heart attacks and strokes - ATERONON™ can potentially extend life and also possibly save lives on a global basis. The potential impact is enormous - we might see a fall in the number of people suffering heart attacks and strokes and other problems relating to arterial damage.

Dr Rob Hicks (GP and TV Doctor)

Lycopene has been proven to reduce the build up of plaques in the arteries and thereby it is automatically reducing the risk for getting a heart attack ... ATERONON™ is built by lycopene.

Alf A. Lindberg (Professor emiritus, Karolinska Institute, Stockholm, Sweden)

ATERONON™ looks to effect the process of metabolism and LDL cholesterol in a very different way to traditional antioxidants and it’s through these types of mechanisms that ATERONON™ holds particular promise as an agent to help reduce the risk of cardiovascular disease over time.

Dr Howard Sesso (Asst Professor of Medicine & Associate Epidemiologist, Brigham Women's Hosp & Harvard Medical School, Boston)

Using a dietary supplement that can implement the inhibition of oxidative stress is one of the goals that we all, as surgeons and cardiologists, must follow in order to prolong survival.

Michele Gulizia (President, Italian Association on Arrhythmias and Cardiac Pacing (AIAC))

With an increasingly ageing population and the incidence of cardiovascular disease throughout society this scientific study presents another breakthrough on the path to reducing this major cause of illness. We have long known that a link exists between diet and the effects of macular disease which affects the sight of one on three people over the age of 75 in Britain and this new breakthrough identifies and strengthens this link which may help in reducing this condition.

Chris Hedges (CEO, Open Sight)

Atherosclerosis, a build up of cholesterol plaque in the arteries, is a significant cause of stroke. We know that diets rich in anti-oxidants are beneficial in reducing the plaque build up and welcome the findings of this research.

Dr Peter Coleman (Deputy Director of Reseach, The Stroke Association)

The new lycopene product ATERONON™ represents an entirely new approach to the treatment of high blood cholesterol and opens up the exciting possibility of limiting the atherogenicity of LDL-cholesterol by preventing its oxidation. The naturally occuring compound lycopene (a carotenoid from tomatoes) has been rendered more bio-available and thus more potent.

Professor Anthony Leeds (Trustee of HEART UK - The Cholesterol Charity)

As the UK's largest pharmacy retailer, our passion is about helping people understand how they can help prevent illness and maintain good health. We're really excited about the launch of ATERONON™ as it represents a potential breakthrough in technology in the supplement market.

Simon McCandlish (Director of Healthcare, Boots UK)